Basic Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. May 24, 2025; 16(5): 103830
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.103830
Figure 1
Figure 1 Immunohistochemical results of homeobox C6. A: Protein expression of homeobox C6 (HOXC6) in para-cancer tissues of bladder cancer (BLCA); B: Protein expression of HOXC6 in BLCA.
Figure 2
Figure 2 Comprehensive evaluation of the mRNA expression and discernibility ability of homeobox C6 in bladder cancer based on global microarray data. A: Forest plot of the homeobox C6 (HOXC6) standardized mean difference in bladder cancer; B: Publication bias by funnel plots of Egger’s test; C: The summary receiver operating characteristic curve of HOXC6. AUC: Area under the curve; SROC: Summary receiver operating characteristic curve; SMD: Standardized mean difference; BLCA: Bladder cancer.
Figure 3
Figure 3 Relative mRNA expression of homeobox C6 in bladder cancer cell lines. A: Relative mRNA expression of homeobox C6 (HOXC6) in EJ-1, 5637, J82, and HT-1376 (compared to the EJ-1 group); B: Relative expression of HOXC6 after transfection with siRNA (compared to 5637 + control group). cP < 0.005; dP < 0.001; CK: Control group; NC: Negative control group; HOXC6: Homeobox C6.
Figure 4
Figure 4 Effect of down-regulated homeobox C6 on cell biological function. A: The CCK-8 test for cell proliferation; B: Cell wound healing assay; C: Transwell experiment; D: Apoptosis assay; E: Cell cycle detection. The 5637 was the blank group. The 5637 + negative control group was the control siRNA group. The 5637 + si-homeobox C6 (HOXC6) group was the transfected with si-HOXC6. Compared to 5637 group. cP < 0.005; dP < 0.001; NC: Negative control group; HOXC6: Homeobox C6.
Figure 5
Figure 5 The result of pathway enrichment analysis with homeobox C6 target genes. BP: Biological process; CC: Cellular component; MF: Molecular function; KEGG: Kyoto Encyclopedia of Genes and Genomes.
Figure 6
Figure 6 The identification of homeobox C6 target genes. A: Venn diagram. I represents the target genes of homeobox C6 (HOXC6) from CistromDB, II represents genes positively correlated with HOXC6 expression in bladder cancer (BLCA), and III represents upregulated genes in BLCA; B: MRNA expression correlation analysis between HOXC6 and TIMELESS; C and D: MRNA expressions of HOXC6 and TIMELESS in BLCA; E: Binding peak of HOXC6 binding to the promoter region of TIMELESS, with data from CistromDB. aP < 0.05; BLCA: Bladder cancer; HOXC6: Homeobox C6.